Pursuant to Regulation 29 (1) (a) and (e) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Abbott India has informed about meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 19, 2017; to consider and approve the text of Audited Financial Results of the Company for the fourth quarter and year ended on March 31, 2017, along with the Audit Report of the Statutory Auditors thereon as required under Regulation 33 of the said Regulations; to consider and approve the Audited Financial Statements for the year ended on March 31, 2017; to recommend final dividend. Further please note that in terms of Abbott India Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window of the Company shall remain closed from Friday, May 12, 2017 to Sunday, May 21, 2017.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: